CAJ | 학술논문

目的：对比冠心病患者应用波利维和泰嘉治疗的临床疗效。方法选自本院2011年至2013年收治的冠心病患者100例，以随机数字表的方式将其分为 a 组和 B 组，每组各有患者50例。2组患者均接受冠心病常规治疗，a 组患者在常规治疗基础上应用波利维，B 组患者在常规治疗基础上应用泰嘉。对2组患者进行平均时间为1年的随访，对比其各项临床指标改善程度以及不良反应概率。结果2组患者治疗后心率、收缩压、心绞痛次数以及住院时间等各项临床指标改善程度对比无显著差异性（P ＞0.05）；2组患者不良反应事件发生概率均为12.0%，对比无统计学意义（P＞0.05）；B 组患者治疗总费用相对于 a 组患者要低很多，对比存在统计学意义（P ＜0.05）。结论对冠心病患者应用波利维和泰嘉进行治疗，均能够收到突出的临床治疗效果，且不会有严重不良反应，但泰嘉药物治疗所需医疗费用较低，可缓解患者经济负担提高其治疗依从性，更具临床应用价值，值得推广。
목적：대비관심병환자응용파리유화태가치료적림상료효。방법선자본원2011년지2013년수치적관심병환자100례，이수궤수자표적방식장기분위 a 조화 B 조，매조각유환자50례。2조환자균접수관심병상규치료，a 조환자재상규치료기출상응용파리유，B 조환자재상규치료기출상응용태가。대2조환자진행평균시간위1년적수방，대비기각항림상지표개선정도이급불량반응개솔。결과2조환자치료후심솔、수축압、심교통차수이급주원시간등각항림상지표개선정도대비무현저차이성（P ＞0.05）；2조환자불량반응사건발생개솔균위12.0%，대비무통계학의의（P＞0.05）；B 조환자치료총비용상대우 a 조환자요저흔다，대비존재통계학의의（P ＜0.05）。결론대관심병환자응용파리유화태가진행치료，균능구수도돌출적림상치료효과，차불회유엄중불량반응，단태가약물치료소수의료비용교저，가완해환자경제부담제고기치료의종성，경구림상응용개치，치득추엄。
Objective to compare patients with coronary heart disease and techno Plavix therapy clinical efficacy. Methods 100 cases of coronary heart disease selected from hospital patients treated in 2011 and 2013 , by way of a random number table will be divided into group a and group B, 50 patients in each group . Group 2 patients received conventional treatment of coronary heart disease , a group of patients with Plavix in the conventional therapy group B patients with techno in conventional therapy . 2 groups of patients for an average time of 1 year follow-up , compared to its degree of improvement in clinical indicators and the probability of adverse reactions . Results the two groups of patients after treatment, the degree of improvement in the clinical parameters of heart rate , systolic blood pressure, angina frequency and length of stay were no significant differences in contrast (P> 0.05); 2 patients the probability of occurrence of adverse events were 12.0% , compared to non- statistically significant (P> 0.05); B group relative to the total cost of treatment of patients in group a patients is much lower , compared to the presence of statistically significant (P <0.05). Conclusion Patients with coronary heart disease and techno Plavix treatment , were able to receive outstanding clinical outcomes , and do not have serious side effects , but taijia lower medical costs needed medications can alleviate the economic burden of patients improve their treatment compliance , more clinical value , worthy of promotion.